Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stock Price Down 0.7% – Time to Sell?

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)’s stock price was down 0.7% during trading on Wednesday . The company traded as low as $67.82 and last traded at $68.02. Approximately 2,083 shares were traded during trading, a decline of 81% from the average daily volume of 11,162 shares. The stock had previously closed at $68.47.

Invesco Biotechnology & Genome ETF Stock Performance

The stock has a market cap of $280.17 million, a PE ratio of 17.12 and a beta of 0.88. The company has a 50 day moving average of $69.75 and a two-hundred day moving average of $66.37.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Institutional investors have recently added to or reduced their stakes in the stock. Carnegie Investment Counsel purchased a new position in Invesco Biotechnology & Genome ETF during the third quarter valued at $204,000. Cetera Investment Advisers lifted its stake in Invesco Biotechnology & Genome ETF by 2.1% in the 2nd quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock valued at $1,808,000 after buying an additional 561 shares in the last quarter. One Capital Management LLC boosted its holdings in Invesco Biotechnology & Genome ETF by 31.9% in the 2nd quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock worth $1,646,000 after buying an additional 6,137 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the 2nd quarter worth approximately $26,000. Finally, Massachusetts Wealth Management raised its holdings in shares of Invesco Biotechnology & Genome ETF by 15.3% during the second quarter. Massachusetts Wealth Management now owns 16,944 shares of the company’s stock valued at $1,098,000 after acquiring an additional 2,245 shares during the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.